176 related articles for article (PubMed ID: 10377424)
1. Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei.
Karpuj MV; Garren H; Slunt H; Price DL; Gusella J; Becher MW; Steinman L
Proc Natl Acad Sci U S A; 1999 Jun; 96(13):7388-93. PubMed ID: 10377424
[TBL] [Abstract][Full Text] [Related]
2. Transglutaminase cross-links in intranuclear inclusions in Huntington disease.
Zainelli GM; Ross CA; Troncoso JC; Muma NA
J Neuropathol Exp Neurol; 2003 Jan; 62(1):14-24. PubMed ID: 12528814
[TBL] [Abstract][Full Text] [Related]
3. Calmodulin regulates transglutaminase 2 cross-linking of huntingtin.
Zainelli GM; Ross CA; Troncoso JC; Fitzgerald JK; Muma NA
J Neurosci; 2004 Feb; 24(8):1954-61. PubMed ID: 14985437
[TBL] [Abstract][Full Text] [Related]
4. Evidence for a role for transglutaminase in Huntington's disease and the potential therapeutic implications.
Karpuj MV; Becher MW; Steinman L
Neurochem Int; 2002 Jan; 40(1):31-6. PubMed ID: 11738470
[TBL] [Abstract][Full Text] [Related]
5. Mutant huntingtin protein: a substrate for transglutaminase 1, 2, and 3.
Zainelli GM; Dudek NL; Ross CA; Kim SY; Muma NA
J Neuropathol Exp Neurol; 2005 Jan; 64(1):58-65. PubMed ID: 15715085
[TBL] [Abstract][Full Text] [Related]
6. Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6/2 mouse model of Huntington's disease.
Dai Y; Dudek NL; Li Q; Fowler SC; Muma NA
J Neurosci; 2009 Sep; 29(37):11550-9. PubMed ID: 19759302
[TBL] [Abstract][Full Text] [Related]
7. Protein aggregation in Huntington's disease.
Hoffner G; Djian P
Biochimie; 2002 Apr; 84(4):273-8. PubMed ID: 12106904
[TBL] [Abstract][Full Text] [Related]
8. Purification of neuronal inclusions of patients with Huntington's disease reveals a broad range of N-terminal fragments of expanded huntingtin and insoluble polymers.
Hoffner G; Island ML; Djian P
J Neurochem; 2005 Oct; 95(1):125-36. PubMed ID: 16181417
[TBL] [Abstract][Full Text] [Related]
9. Tissue transglutaminase selectively modifies proteins associated with truncated mutant huntingtin in intact cells.
Chun W; Lesort M; Tucholski J; Faber PW; MacDonald ME; Ross CA; Johnson GV
Neurobiol Dis; 2001 Jun; 8(3):391-404. PubMed ID: 11442349
[TBL] [Abstract][Full Text] [Related]
10. Experimental mutagenesis of huntingtin to map cleavage sites: different outcomes in cell and mouse models.
Tebbenkamp AT; Xu G; Siemienski ZB; Janus C; Fromholt SE; Brown HH; Swing D; Tessarollo L; Borchelt DR
J Huntingtons Dis; 2014; 3(1):73-86. PubMed ID: 25062766
[TBL] [Abstract][Full Text] [Related]
11. Huntingtin inclusions do not deplete polyglutamine-containing transcription factors in HD mice.
Yu ZX; Li SH; Nguyen HP; Li XJ
Hum Mol Genet; 2002 Apr; 11(8):905-14. PubMed ID: 11971872
[TBL] [Abstract][Full Text] [Related]
12. Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions.
Lunkes A; Lindenberg KS; Ben-Haïem L; Weber C; Devys D; Landwehrmeyer GB; Mandel JL; Trottier Y
Mol Cell; 2002 Aug; 10(2):259-69. PubMed ID: 12191472
[TBL] [Abstract][Full Text] [Related]
13. The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis.
Holbert S; Denghien I; Kiechle T; Rosenblatt A; Wellington C; Hayden MR; Margolis RL; Ross CA; Dausset J; Ferrante RJ; Néri C
Proc Natl Acad Sci U S A; 2001 Feb; 98(4):1811-6. PubMed ID: 11172033
[TBL] [Abstract][Full Text] [Related]
14. In vitro evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease.
Hackam AS; Singaraja R; Zhang T; Gan L; Hayden MR
Hum Mol Genet; 1999 Jan; 8(1):25-33. PubMed ID: 9887328
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of apoptosis signal-regulating kinase 1 reduces endoplasmic reticulum stress and nuclear huntingtin fragments in a mouse model of Huntington disease.
Cho KJ; Lee BI; Cheon SY; Kim HW; Kim HJ; Kim GW
Neuroscience; 2009 Nov; 163(4):1128-34. PubMed ID: 19646509
[TBL] [Abstract][Full Text] [Related]
16. Interaction of the nuclear matrix protein NAKAP with HypA and huntingtin: implications for nuclear toxicity in Huntington's disease pathogenesis.
Sayer JA; Manczak M; Akileswaran L; Reddy PH; Coghlan VM
Neuromolecular Med; 2005; 7(4):297-310. PubMed ID: 16391387
[TBL] [Abstract][Full Text] [Related]
17. Calpain activation in Huntington's disease.
Gafni J; Ellerby LM
J Neurosci; 2002 Jun; 22(12):4842-9. PubMed ID: 12077181
[TBL] [Abstract][Full Text] [Related]
18. Prefibrillar huntingtin oligomers isolated from HD brain potently seed amyloid formation.
Morozova OA; Gupta S; Colby DW
FEBS Lett; 2015 Jul; 589(15):1897-903. PubMed ID: 26037141
[TBL] [Abstract][Full Text] [Related]
19. Tissue transglutaminase does not contribute to the formation of mutant huntingtin aggregates.
Chun W; Lesort M; Tucholski J; Ross CA; Johnson GV
J Cell Biol; 2001 Apr; 153(1):25-34. PubMed ID: 11285271
[TBL] [Abstract][Full Text] [Related]
20. Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration.
Dong X; Zong S; Witting A; Lindenberg KS; Kochanek S; Huang B
J Gene Med; 2012 Jul; 14(7):468-81. PubMed ID: 22700462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
